Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Capital Reinvestment Ratio
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. capital reinvestment ratio. Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) has a Capital Reinvestment Ratio of 7.61x as of December 2023, meaning it reinvests 8% of its operating cash flow (CN¥90.45 Million) in capital expenditures (CN¥688.60 Million). Check 301096 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (2019–2023)
Capital reinvestment ratio of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. from 2019 to 2023. This chart tracks Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s Capital Reinvestment Ratio across 5 annual periods. Also explore 301096 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Capital Reinvestment Ratio by Year (2019–2023)
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. capital reinvestment ratio by year from 2019 to 2023. For the full cash flow conversion analysis, see 301096 cash flow metrics.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 7.61x | CN¥90.45 Million | CN¥688.60 Million | ▲ +233.8% |
| 2022 | 2.28x | CN¥259.41 Million | CN¥591.58 Million | ▲ +33.5% |
| 2021 | 1.71x | CN¥145.42 Million | CN¥248.45 Million | ▼ -63.6% |
| 2020 | 4.69x | CN¥54.36 Million | CN¥255.12 Million | ▲ +213.6% |
| 2019 | 1.50x | CN¥71.47 Million | CN¥106.95 Million | — |